Diabetes &
Primary Care

Issue:

Share this article

+ Add to reading list - Remove from my list

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Stephen Bain

An unexpected safety signal emerged from the SUSTAIN 6 cardiovascular outcomes trial of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide, whereby increased rates of diabetic retinopathy were observed in trial participants randomised to semaglutide. This finding has, justifiably, led to a great deal of investigation and caution. This At a Glance factsheet outlines the evidence regarding diabetic retinopathy in users of the GLP-1 RA class as a whole, and provides recommendations on safe use.

Save, Share, Print Article

Share this article

+ Add to reading list – Remove from reading list

↓ Download pdf

Readers are directed to the PDF version of this article.

At a glance factsheet, Microvascular complications, Newer therapies, Retinopathy

Diabetes &
Primary Care

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Scottish Government and NHS Scotland consensus statement on GLP-1-based therapies for obesity

Editorial: Type 2 diabetes, CVD, CKD, dementia and health inequality: Adopting a preventative approach

The dialysis timebomb: Why preventing kidney disease is everyone’s responsibility

Conference over coffee: Oncology, end-of-life care, psychology and insulin dilemmas

How to follow up gestational diabetes

Prescribing pearls: A guide to pioglitazone

Interactive case study: Antiplatelet treatment in diabetes